lung cancer

[Cell Death Discovery] Researchers performed GEO dataset analysis and identified that claudin1 was a critical regulator of epidermal growth factor receptor tyrosine kinase inhibitors resistance in NSCLC cells.

[Scientific Reports] Physiochemical properties, encapsulation efficiency, loading content and in vitro release kinetics of DOX were assessed in MUC1 aptamer-functionalized PLA-PEG nanocarriers targeting lung cancer cells.

[Seminars in Cancer Biology] The authors review the advancements in transformed SCLC, including clinical and pathological characteristics, and the potential effective treatment after SCLC transformation, aiming to give a better understanding of transformed SCLC and provide support for clinical uses.

[Seminars in Cancer Biology] Scientists summarize the roles of distinct immunogenic cell death mechanisms on antitumor immunity and recent advances of ferroptosis-, necroptosis- and pyroptosis-inducing agents, and present perspectives on these cell death mechanisms in immunotherapy of SCLC.

[Thoracic Cancer] Investigators outline the basic structure and generation characteristic of chimeric antigen receptor-modified T (CAR-T) cells and summarize the common tumor-associated antigens in clinical trials of CAR-T cell therapy for lung cancer.

[Foundation Medicine, Inc.] Foundation Medicine, Inc. announced it has received approval from the US FDA for FoundationOne®CDx to be used as a companion diagnostic to identify patients with NSCLC.